Masimo Corporation’s (MASI - Free Report) flagship Rad-97 Pulse CO-Oximeter with integrated NomoLine capnography recently obtained CE mark. This will make the device available in and outside the United States in three configurations: Rad-97, Rad-97 with integrated noninvasive blood pressure, and Rad-97 with NomoLine capnography.
Last November, Rad-97 with NomoLine capnography received FDA 510(k) clearance.
Masimo Eyes Capnography Markets
Respiratory tribulation is one of the most common patient complaints in the United States. Capnography is an important tool to determine the cause and severity of respiratory distress by monitoring the respiration process.
A research report by the HealthyPeople suggests that more than 25 million people in the United States are suffering from asthama — a severe respiratory illness. In fact, annual health care expenditures for asthma alone are estimated at $20.7 billion currently.
We believe Masimo’s focus on the Capnography market is strategic considering the increasing profitability in the niche space.
In fact, per a report by Transparency Market Research, the global respiratory monitoring devices market will see a CAGR of 8.27% in the 2017 to 2023 period to $2.8 million.
Masimo NomoLine in Focus
In the fourth quarter of 2017, Masimo’s NomoLine along with SedLine Brain Function Monitoring and O3 organ oximetry accounted for a 40% year-over-year increase in product revenues.
Notably, the Masimo NomoLine is a no moisture sampling technology. It is capable of eliminating many common problems in conventional gas sampling line systems. NomoLine sampling lines can be used in a variety of clinical scenarios in adult, pediatric, infant and neonatal patients, with low tidal volumes and high breath rates.
Rad-97 with NomoLine capnography features an integrated ISA CO2 module and meets continuous monitoring and capnography needs through a single device.
We believe the latest developments will cushion Masimo’s stock that has lost 9.5%, against the industry’s rally of 15.2% over the past year.
Zacks Rank & Other Key Picks
Masimo carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are BIOHAVEN PHARM (BHVN - Free Report) , Bio-Rad Laboratories, Inc. (BIO - Free Report) and Envision Healthcare Corporation . While BIOHAVEN and Bio-Rad sport a Zacks Rank #1 (Strong Buy), Envision carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
BIOHAVEN has an expected growth rate of 50% for the current quarter and 42.1% for the next quarter.
Bio-Rad has an expected long-term growth rate of 20% and 42.9% for the current year.
Envision has an expected long-term growth rate of 13% and 10.6% for the next quarter.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>